Last reviewed · How we verify
SPECT
Spect works by interacting with a specific biological target to produce a therapeutic effect.
Spect is a small molecule drug developed by the Tomsk National Research Medical Center of the Russian Academy of Sciences. Its target and drug class are unknown, but it is currently owned by the same institution. Spect is off-patent, meaning there are no active patents protecting it. As a result, there are no generic manufacturers of the drug. The commercial status and approved indications of Spect are unclear.
At a glance
| Generic name | SPECT |
|---|---|
| Also known as | 99mTc-ZHER2:41071, [123I] I-(HE)3-G3 |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Target | 30S ribosomal protein S12 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like locks, and Spect is a key that fits into one of those locks. When Spect binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as reducing symptoms of a disease. This process is highly specific, meaning Spect only affects the cells it's designed to target.
Approved indications
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Disseminated Gonococcal Infection
- Gonorrhea
- Gonorrhea of rectum
Common side effects
Key clinical trials
- SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
- Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment (PHASE1)
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC (PHASE1)
- Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (PHASE2)
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (PHASE1)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |